MCID: CRV031
MIFTS: 48

Cervical Adenocarcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cervical Adenocarcinoma

MalaCards integrated aliases for Cervical Adenocarcinoma:

Name: Cervical Adenocarcinoma 11 58 53 14 16 71
Adenocarcinoma of the Uterine Cervix 11
Adenocarcinoma of the Cervix Uteri 58
Adenocarcinoma Cervix Uteri 11
Adenocarcinoma of Cervix 11

Characteristics:


Prevelance:

Adenocarcinoma of the Cervix Uteri: 1-9/100000 (Europe, Bulgaria, Czech Republic, Iceland, Lithuania, Norway, Portugal, Slovakia, Slovenia) 1-9/1000000 (Austria, Belgium, Croatia, Estonia, Finland, Germany, Ireland, Italy, Latvia, Malta, Poland, Spain, Switzerland, Netherlands, United Kingdom) 58

Age Of Onset:

Adenocarcinoma of the Cervix Uteri: Adult 58

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 11 DOID:3702
NCIt 49 C4029
SNOMED-CT 68 254887002
ICD10 via Orphanet 32 C53.0 C53.1 C53.8
UMLS via Orphanet 72 C0279672
Orphanet 58 ORPHA213772
ICD11 33 261293318
UMLS 71 C0279672

Summaries for Cervical Adenocarcinoma

Disease Ontology: 11 A cervix carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Cervical Adenocarcinoma, also known as adenocarcinoma of the uterine cervix, is related to cervical clear cell adenocarcinoma and cervical mucinous adenocarcinoma. An important gene associated with Cervical Adenocarcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Signal Transduction and Signaling by Receptor Tyrosine Kinases. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and endothelial, and related phenotypes are neoplasm and normal

Related Diseases for Cervical Adenocarcinoma

Diseases in the Cervical Adenocarcinoma family:

Early Invasive Cervical Adenocarcinoma

Diseases related to Cervical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 612)
# Related Disease Score Top Affiliating Genes
1 cervical clear cell adenocarcinoma 32.2 KRT7 CDKN2A
2 cervical mucinous adenocarcinoma 32.1 PGR KRT7 CDKN2A
3 cervical serous adenocarcinoma 32.1 PGR CEACAM5
4 adenocarcinoma 31.4 TP53 KRT7 KRT20 KRAS CXCL12 CEACAM5
5 adenocarcinoma in situ 31.4 TP53 KRT7 KRAS CEACAM5 CDX2 CDKN2A
6 suppressor of tumorigenicity 3 31.3 TP53 CDKN2A CDKN1A
7 cervical squamous cell carcinoma 30.8 TP53 RASSF1 MKI67 KRAS CEACAM5 CDKN2A
8 endocervical adenocarcinoma 30.8 TP53 PGR KRT7 ESR1 CEACAM5 CDKN2A
9 adenosquamous carcinoma 30.8 PGR NME1 KRT7 KRT20 KRAS CEACAM7
10 papillary transitional carcinoma 30.7 TP53 KRT7 KRT20
11 hepatoid adenocarcinoma 30.7 KRT7 CEACAM5 CDX2
12 cervical cancer 30.7 TP53 RASSF1 NME1 EBAG9 CDKN2A CDKN1A
13 papillary serous adenocarcinoma 30.7 TP53 PGR KRT7 KRAS ESR1 CEACAM5
14 papilloma 30.7 TP53 RASSF1 KRT7 KRT20 KRAS CDKN2A
15 signet ring cell adenocarcinoma 30.6 TP53 KRT7 KRT20 KRAS CEACAM5 CDX2
16 bilateral breast cancer 30.5 TP53 PGR ESR1 CDKN2A
17 appendix adenocarcinoma 30.5 TP53 KRT7 KRT20 KRAS CEACAM5 CDX2
18 pancreatic adenocarcinoma 30.5 TP53 KRAS CXCL12 CDKN2A CDKN1A
19 vulval paget's disease 30.4 KRT7 CEACAM5 CDKN2A
20 vaginal cancer 30.4 TP53 PGR KRT7 ESR1 CDKN2A
21 ovarian cystadenocarcinoma 30.4 TP53 KRAS ESR1 CEACAM5 CDKN2A
22 squamous cell carcinoma 30.4 TP53 NME1 MKI67 LAMC2 KRT7 KRAS
23 mucinous cystadenocarcinoma 30.4 KRT7 KRT20 KRAS CEACAM7 CEACAM5 CDX2
24 rectal benign neoplasm 30.4 TP53 KRT7 KRT20 KRAS CEACAM5 CDX2
25 mucinous adenocarcinoma 30.4 TP53 KRT7 KRT20 KRAS CEACAM5 CDX2
26 rectum cancer 30.3 TP53 KRT20 KRAS CEACAM7 CEACAM5 CDKN1A
27 small cell carcinoma 30.3 TP53 KRT7 KRT20 CEACAM5
28 transitional cell carcinoma 30.3 TP53 NME1 MKI67 KRT7 KRT20 CDKN1A
29 cystadenocarcinoma 30.3 TP53 PGR KRT7 KRAS CEACAM5 CDKN1A
30 serous cystadenocarcinoma 30.3 TP53 PGR KRT7 KRAS ESR1 CDKN2A
31 neuroendocrine carcinoma 30.3 PGR KRT7 KRT20 ESR1
32 cystitis 30.3 TP53 KRT7 KRT20
33 breast lobular carcinoma 30.2 TP53 PGR KRT7 ESR1
34 leiomyoma 30.2 TP53 PGR MKI67 ESR1
35 vaginal discharge 30.2 PGR KRT7 ESR1 CEACAM5
36 adenoid squamous cell carcinoma 30.2 TP53 KRT7 CEACAM5
37 large cell neuroendocrine carcinoma 30.2 TP53 KRT7 KRAS
38 breast fibroadenoma 30.2 TP53 RASSF1 PGR NME1 MKI67 ESR1
39 cervix endometriosis 30.2 CDKN2A CALB2
40 endometrial adenocarcinoma 30.2 TP53 PGR KRT7 KRAS ESR1 CDKN2A
41 cervical polyp 30.2 PGR ESR1
42 ovary adenocarcinoma 30.1 TP53 PGR KRT7 KRAS ESR1 CEACAM5
43 mammary paget's disease 30.1 PGR KRT7 KRT20 ESR1 CEACAM5
44 intestinal obstruction 30.1 KRT7 KRT20 CEACAM5 CDX2
45 cervix carcinoma 30.1 TP53 PGR KRT7 KRAS ESR1 CEACAM5
46 human papillomavirus infectious disease 30.1 TP53 CDKN2A CDKN1A
47 vulva cancer 30.1 TP53 KRT7 CEACAM5 CDKN2A
48 adenomyoma 30.0 PGR KRT7 ESR1 CDKN2A
49 uterine carcinosarcoma 30.0 TP53 KRAS ESR1
50 adenoma 30.0 TP53 MKI67 KRT7 KRT20 KRAS CDX2

Graphical network of the top 20 diseases related to Cervical Adenocarcinoma:



Diseases related to Cervical Adenocarcinoma

Symptoms & Phenotypes for Cervical Adenocarcinoma

GenomeRNAi Phenotypes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.15 CALB2 CDKN1A CDKN2A CDX2 CEACAM5 CEACAM7
2 no effect GR00402-S-2 10.15 CALB2 CDKN1A CDKN2A CDX2 CEACAM5 CEACAM7

MGI Mouse Phenotypes related to Cervical Adenocarcinoma:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.31 CDKN1A CDKN2A CDX2 CEACAM5 CXCR4 ESR1
2 normal MP:0002873 10.22 CALB2 CDX2 CEACAM7 CXCL12 ESR1 KRAS
3 cellular MP:0005384 10.18 CDKN1A CDKN2A CDX2 CEACAM5 CXCL12 CXCR4
4 endocrine/exocrine gland MP:0005379 10.17 CDKN1A CDKN2A CDX2 CEACAM5 CXCR4 ESR1
5 muscle MP:0005369 10.15 CDKN1A CDKN2A CEACAM5 CXCL12 CXCR4 ESR1
6 no phenotypic analysis MP:0003012 10.11 CDKN1A CDKN2A CXCL12 ESR1 KRAS MKI67
7 digestive/alimentary MP:0005381 10.1 CDKN1A CDKN2A CDX2 CEACAM5 CXCR4 ESR1
8 immune system MP:0005387 10.1 CDKN1A CDKN2A CEACAM5 CEACAM7 CXCL12 CXCR4
9 liver/biliary system MP:0005370 10.08 CDKN1A CDKN2A CXCL12 ESR1 KRAS NME1
10 cardiovascular system MP:0005385 10.06 CDKN1A CDKN2A CDX2 CEACAM5 CXCL12 CXCR4
11 limbs/digits/tail MP:0005371 10 CDKN1A CDX2 ESR1 KRAS LAMC2 PGR
12 skeleton MP:0005390 9.85 CDKN1A CDKN2A CDX2 CEACAM7 CXCR4 ESR1
13 mortality/aging MP:0010768 9.8 CDKN1A CDKN2A CDX2 CEACAM5 CEACAM7 CXCL12
14 integument MP:0010771 9.32 CDKN1A CDKN2A CEACAM7 CXCR4 ESR1 KRAS

Drugs & Therapeutics for Cervical Adenocarcinoma

Drugs for Cervical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
2
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
3
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60699 60700
4
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
5
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
6
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
7
Tirapazamine Investigational Phase 3 27314-97-2 135413511
8 Antiviral Agents Phase 3
9 Anti-Infective Agents Phase 3
10 Antimetabolites Phase 3
11 Albumin-Bound Paclitaxel Phase 3
12 Antimitotic Agents Phase 3
13 Tubulin Modulators Phase 3
14 topoisomerase I inhibitors Phase 3
15
Epoetin Alfa Phase 3
16 Hematinics Phase 3
17 Chrysarobin Phase 3
18 Immunosuppressive Agents Phase 3
19 Immunologic Factors Phase 3
20 Vaccines Phase 3
21
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
22
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
23
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
24
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
25
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
26
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
27
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
28
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
29
Lenograstim Approved, Investigational Phase 2 135968-09-1
30
Ipilimumab Approved Phase 2 477202-00-9
31
Nivolumab Approved Phase 2 946414-94-4
32
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
33
Veliparib Investigational Phase 2 912444-00-9 11960529
34 Immunoglobulins, Intravenous Phase 2
35 Immunoglobulin G Phase 2
36 Antibodies, Monoclonal Phase 2
37 Fluorodeoxyglucose F18 Phase 1, Phase 2
38 Angiogenesis Inhibitors Phase 2
39 Endothelial Growth Factors Phase 2
40 Mitogens Phase 2
41 Protein Kinase Inhibitors Phase 2
42 Anti-Bacterial Agents Phase 2
43 Antifungal Agents Phase 2
44 Antibiotics, Antitubercular Phase 2
45 Adjuvants, Immunologic Phase 2
46 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
47 Immunoglobulins Phase 2
48 Immune Checkpoint Inhibitors Phase 2
49 Antibodies Phase 2
50 Antineoplastic Agents, Immunological Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
2 Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer Completed NCT00017004 Phase 3 Cisplatin
3 A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial Completed NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
5 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451) Active, not recruiting NCT01101451 Phase 3 Cisplatin
6 A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Active, not recruiting NCT02466971 Phase 3 Cisplatin;Triapine
7 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
8 A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
9 A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA Completed NCT00369122 Phase 2 Cisplatin
10 A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies Completed NCT01693783 Phase 2
11 A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Cervical Cancer Completed NCT00559377 Phase 2
12 A Simplified Approach of Complete Nerve-sparing Type C1 Radical Hysterectomy for Cervical Cancer, a Phase II Study Completed NCT02562729 Phase 2
13 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
14 A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma Completed NCT00389974 Phase 2 sunitinib malate
15 A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix Completed NCT00039442 Phase 2 Capecitabine
16 A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
17 Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
18 A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
19 A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix Completed NCT01026792 Phase 2 Temsirolimus
20 A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Completed NCT01266460 Phase 2
21 A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
22 A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048) Completed NCT01267253 Phase 2 Brivanib Alaninate
23 A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer Completed NCT02921269 Phase 2 Atezolizumab
24 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
25 A Prospective Open Label Phase II Study to Optimize the Dose in 3D Pulsed Dose Rate Brachytherapy in Patients With Locally Advanced Cervical Cancer Completed NCT02880007 Phase 2 Cisplatin
26 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
27 A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer Active, not recruiting NCT02257528 Phase 2
28 Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma: A Phase II Single-arm Clinical Study Not yet recruiting NCT05259540 Phase 2 compound kushen injection combined with pabolizumab
29 A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer Terminated NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
30 A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Paclitaxel and Carboplatin in HIV-positive Women With Locally Advanced Cervical Cancer (LACC) Withdrawn NCT03834571 Phase 2 Carboplatin;Cisplatin;Paclitaxel
31 A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes Unknown status NCT01295502 Phase 1 Carboplatin;Cisplatin;Paclitaxel
32 A Phase I Trial of Tailored Radiation Therapy With Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients With Cervical Cancer Completed NCT00104910 Phase 1 Cisplatin
33 A PHASE I STUDY OF PELVIC RADIATION THERAPY WITH CONCOMITANT WEEKLY CISPLATIN AND TOPOTECAN CHEMOTHERAPY IN PATIENTS WITH CERVICAL CARCINOMA WITHOUT EXTRA-PELVIC METASTASIS Completed NCT00054444 Phase 1 Topotecan Hydrochloride Liposomes;Cisplatin
34 A Phase I Study of Whole Pelvic Radiation Therapy With Concomitant Cisplatin and Gemcitabine Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis Completed NCT00068549 Phase 1 Gemcitabine Hydrochloride;Cisplatin
35 A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix Completed NCT01281852 Phase 1 Cisplatin;Paclitaxel;Veliparib
36 A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients With Locally Advanced Cervical Cancer Stages IB2/IIA With Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA With Positive Lymph Nodes Completed NCT01711515 Phase 1 Cisplatin
37 Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer Recruiting NCT02595879 Phase 1 Cisplatin;Triapine
38 Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex) Recruiting NCT02020707 Phase 1 Nab-paclitaxel
39 Phase I Multi-Center Study of Hypofractionated Radiotherapy in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer Active, not recruiting NCT03452332 Phase 1
40 Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer Active, not recruiting NCT03738228 Phase 1 Atezolizumab;Cisplatin
41 A Multi-omics Study on the Human Papillomavirus Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma Unknown status NCT03742869
42 Observational Study for Determine the Presence and Genotypes of HVP Infection in Cervical Intraepithelial Neoplasia Grade II-III (CIN II-III), and Stage I Cervical Epidermoid Carcinoma and Cervical Adenocarcinoma. Completed NCT00937547
43 Glycoprotein and Glycan Profiling in Patients With Locally Advanced Cervical Cancer (Stage IB2, IIA > 4 CM, IIB to IVA) Undergoing Pelvic and Para-aortic (Abdominal) Lymphadenectomy Completed NCT00460356
44 Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer Completed NCT00897442
45 Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021
46 Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix - a Rare Tumor Recruiting NCT05046080
47 Yoga Therapy During Chemotherapy and Radiation Treatment for Local-Regional Cervical Cancer Recruiting NCT04622670
48 Clinical Evaluation Study of Urine hrHPV Detection for the Diagnosis of Presence of Cervical HPV and Correlation of Cervical Lesions Recruiting NCT05210348
49 MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix Active, not recruiting NCT01992861
50 Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer Active, not recruiting NCT01649089

Search NIH Clinical Center for Cervical Adenocarcinoma

Genetic Tests for Cervical Adenocarcinoma

Anatomical Context for Cervical Adenocarcinoma

Organs/tissues related to Cervical Adenocarcinoma:

MalaCards : Cervix, Lymph Node, Endothelial, Uterus, Breast, Lung, T Cells

Publications for Cervical Adenocarcinoma

Articles related to Cervical Adenocarcinoma:

(show top 50) (show all 1876)
# Title Authors PMID Year
1
P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. 53 62
20524403 2010
2
Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma. 53 62
18202755 2008
3
The biological role of the unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. 53 62
17981616 2008
4
Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. 53 62
18156982 2008
5
Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. 53 62
17252195 2007
6
Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality. 53 62
17354237 2007
7
Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. 53 62
17360030 2007
8
[Correlation of CXCR4/CXCL12 overexpression to lymph node metastasis and chronic inflammation in cervical adenocarcinoma]. 53 62
17355795 2007
9
Immunohistochemistry as a diagnostic aid in cervical pathology. 53 62
17365826 2007
10
Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis. 53 62
16290001 2006
11
Immunohistochemical characterization of endocervical papillary serous carcinoma. 53 62
16515605 2006
12
p16 expression in the female genital tract and its value in diagnosis. 53 62
16462152 2006
13
The clinicopathologic significance of laminin-5 gamma2 chain expression in cervical squamous carcinoma and adenocarcinoma. 53 62
16343183 2005
14
Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: P53 status has a strong impact on prognosis. 53 62
15337561 2004
15
The role of the preoperative serum carcinoembryonic antigen level in early-stage adenocarcinoma of the uterine cervix. 53 62
15297173 2004
16
P16 as a molecular biomarker of cervical adenocarcinoma. 53 62
15041997 2004
17
Correlation between MUC5AC expression and the prognosis of patients with adenocarcinoma of the uterine cervix. 53 62
14699032 2004
18
Primary cervical adenocarcinoma with intestinal differentiation and colonic carcinoma metastatic to cervix: an investigation using Cdx-2 and a limited immunohistochemical panel. 53 62
14632574 2003
19
CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. 53 62
12877729 2003
20
Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. 53 62
11248419 2001
21
The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. 53 62
11104614 2000
22
Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. 53 62
11006578 2000
23
Abnormal expression of sex steroid receptors and cell cycle-related molecules in adenocarcinoma in situ of the uterine cervix. 53 62
10202666 1999
24
Evaluation of immunostaining for MIB1 and nm23 products in uterine cervical adenocarcinoma. 53 62
9823779 1998
25
Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. 53 62
9635534 1998
26
Tumour-associated antigens CEA, CA125, SCC and TPS in gynaecological cancer. 53 62
9476065 1998
27
[Relationship between nm23-H1 expression and lymph node metastasis and prognosis in cervical cancer]. 53 62
9772433 1997
28
Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. 53 62
9314589 1997
29
Molecular characterization of adenocarcinoma of the cervix. 53 62
9038270 1997
30
What is a normal CA125 level? 53 62
8175027 1994
31
Expression and prognostic significance of estrogen and progesterone receptors in adenocarcinoma of the uterine cervix. An immunocytochemical study. 53 62
8319181 1993
32
Oestrogen receptor protein and mRNA in adenocarcinoma of the uterine cervix. 53 62
1457356 1992
33
Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma. 53 62
2258083 1990
34
Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics. 53 62
2317761 1990
35
Mucin leakage into the cervical stroma may increase lymph node metastasis in mucin-producing cervical adenocarcinomas. 53 62
2153042 1990
36
Distribution and incidence of atypical glandular lesions in cervical cytology focusing on the association with high-risk human papillomavirus subtypes. 62
36419751 2023
37
Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype. 62
36455190 2022
38
Convolutional Neural Networks for Classifying Cervical Cancer Types Using Histological Images. 62
36474087 2022
39
Identification of novel genetic and epigenetic regulators of different tissue types of cervical cancer. 62
36184073 2022
40
Atypical glandular cells and development of cervical cancer: Population-based cohort study. 62
36029205 2022
41
Cervical adenocarcinoma admixing with large cell neuroendocrine carcinoma: A rare case report. 62
35778245 2022
42
Pathological classification of desmoplastic reaction is prognostic factor in cervical adenocarcinoma. 62
35876908 2022
43
Oncologic outcomes of patients with FIGO 2014 stage IB-IIA cervical adenocarcinoma who underwent radical surgery. 62
35303151 2022
44
Comparison of the safety between cervical conization and hysterectomy for patients with cervical adenocarcinoma in situ. 62
36424703 2022
45
Invasive stratified mucin-producing carcinoma (ISMC) of uterine cervix: description of pathological findings and prognosis factors in a series of 15 Chinese patients. 62
35394200 2022
46
Value of non-Gaussian diffusion imaging with a fractional order calculus model combined with conventional MRI for differentiating histological types of cervical cancer. 62
35988835 2022
47
LncRNA MEG3 promotes cisplatin sensitivity of cervical cancer cells by regulating the miR-21/PTEN axis. 62
36344947 2022
48
Adenocarcinoma of the uterine cervix, gastric-type (GAS): a review of the literature focused on pathology and multimodality imaging. 62
36334123 2022
49
Patterns and risk factors of recurrence in low-risk early-stage cervical adenocarcinoma treated with surgery alone: implications on risk group stratification. 62
36368708 2022
50
Immunohistochemical and molecular analysis of an α-fetoprotein-producing cervical adenocarcinoma with clear cell morphology. 62
36183278 2022

Variations for Cervical Adenocarcinoma

Expression for Cervical Adenocarcinoma

Search GEO for disease gene expression data for Cervical Adenocarcinoma.

Pathways for Cervical Adenocarcinoma

Pathways related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1 13.61 CDKN1A CXCL12 CXCR4 EBAG9 ESR1 KRAS
2 12.68 PGR LAMC2 KRAS ESR1 CXCL12
3
Show member pathways
12.45 TP53 RASSF1 KRAS CDKN2A CDKN1A
4
Show member pathways
12.25 CXCL12 CXCR4 ESR1 KRAS
5 12.24 TP53 RASSF1 LAMC2 CXCL12 CDKN2A CDKN1A
6
Show member pathways
12.19 PGR ESR1 CDKN2A CDKN1A
7
Show member pathways
12.15 CDKN1A ESR1 KRAS PGR TP53
8
Show member pathways
12.07 TP53 KRAS CXCR4 CDKN1A
9
Show member pathways
11.79 PGR KRAS ESR1 CXCL12
10
Show member pathways
11.77 TP53 RASSF1 CDKN2A
11 11.75 TP53 LAMC2 CDKN1A
12 11.59 TP53 CXCR4 CXCL12
13 11.53 TP53 ESR1 CDKN2A
14 11.47 PGR ESR1 EBAG9
15 11.28 TP53 RASSF1 CDKN2A
16 11.12 TP53 KRAS CDKN2A CDKN1A
17
Show member pathways
10.73 TP53 CDKN2A CDKN1A
18 10.69 PGR ESR1
19 10.62 TP53 RASSF1 KRAS CDKN2A CDKN1A
20
Show member pathways
10.4 CDKN1A TP53
21 10.23 TP53 CDKN1A

GO Terms for Cervical Adenocarcinoma

Biological processes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.67 TP53 ESR1
2 telencephalon cell migration GO:0022029 9.62 CXCR4 CXCL12
3 response to ultrasound GO:1990478 9.46 CXCR4 CXCL12
4 signal transduction by p53 class mediator GO:0072331 9.43 TP53 CDKN1A
5 replicative senescence GO:0090399 9.43 TP53 CDKN2A CDKN1A
6 Ras protein signal transduction GO:0007265 9.32 TP53 RASSF1 KRAS CDKN2A CDKN1A

Sources for Cervical Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....